Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $10.0833.

Several brokerages have issued reports on XERS. Oppenheimer restated an “outperform” rating and issued a $18.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Barclays assumed coverage on Xeris Biopharma in a research report on Monday, December 8th. They issued an “overweight” rating and a $9.00 price objective for the company. Piper Sandler lifted their price target on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th.

Xeris Biopharma Stock Up 2.2%

Shares of NASDAQ:XERS opened at $6.07 on Thursday. The company has a 50 day moving average price of $7.16 and a two-hundred day moving average price of $7.61. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.35 and a current ratio of 2.19. The company has a market capitalization of $1.05 billion, a PE ratio of -606.39 and a beta of 0.61. Xeris Biopharma has a 52 week low of $3.65 and a 52 week high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The company had revenue of $85.81 million during the quarter, compared to analyst estimates of $86.00 million. Analysts forecast that Xeris Biopharma will post -0.41 earnings per share for the current year.

Key Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Analyst support — HC Wainwright reiterated a “Buy” rating and a $10 price target while publishing multi-year EPS models that show the company returning to positive earnings by FY2026 and rising thereafter; that bullish stance supports investor optimism. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright
• Positive Sentiment: Earnings beat — Xeris reported Q4 2025 adjusted EPS above consensus (roughly $0.0615 vs. $0.03 expected), indicating improving profitability that investors are rewarding. Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
• Positive Sentiment: Bull thesis coverage — A Seeking Alpha piece argues Xeris is undervalued given its drug portfolio upside, which can attract value-oriented and growth investors. Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio
• Neutral Sentiment: Profitability vs. legal risk — Coverage highlights that Xeris has achieved new profitability metrics but is simultaneously engaged in patent disputes over Recorlev; this balances upside with legal uncertainty, creating a mixed signal for investors. Xeris Biopharma Balances New Profitability With Recorlev Patent Battles
• Negative Sentiment: Insider sale — Director/insider Beth Hecht sold 16,667 shares at about $6.25 on March 2, modestly reducing her stake; insider selling can raise caution among investors even if the position remains large. SEC Form 4 — Beth Hecht
• Negative Sentiment: Analyst estimate cuts — Although HC Wainwright kept a Buy rating, it trimmed several multi-year EPS forecasts (FY2026–FY2029/FY2030 adjustments), which reduces the magnitude of long-term upside implied by prior models. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright

Insider Transactions at Xeris Biopharma

In other news, insider John Patrick Shannon, Jr. sold 24,907 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $7.08, for a total value of $176,341.56. Following the sale, the insider directly owned 2,705,346 shares in the company, valued at $19,153,849.68. The trade was a 0.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $6.25, for a total value of $104,168.75. Following the transaction, the insider directly owned 1,226,507 shares of the company’s stock, valued at $7,665,668.75. This represents a 1.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 240,308 shares of company stock worth $1,732,453. 6.47% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares during the last quarter. Geode Capital Management LLC grew its position in Xeris Biopharma by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after purchasing an additional 135,815 shares in the last quarter. State Street Corp increased its stake in Xeris Biopharma by 10.1% in the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after buying an additional 378,595 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in Xeris Biopharma by 6.0% during the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after buying an additional 185,063 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares in the last quarter. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.